Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Zur Rose Group AG    ROSE   CH0042615283

ZUR ROSE GROUP AG

(ROSE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Zur Rose Group: Acquisition of medpex successfully concluded

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/07/2019 | 01:05am EDT

EQS Group-News: Zur Rose Group AG / Key word(s): Mergers & Acquisitions
Zur Rose Group: Acquisition of medpex successfully concluded

07.01.2019 / 07:00


Press release

Zur Rose Group: Acquisition of medpex successfully concluded

The Zur Rose Group has successfully completed the acquisition of the e-commerce activities of Germany's third-largest online pharmacy medpex. In the course of this transaction, the Group acquired Comventure GmbH in Forst (Germany), Visionrunner GmbH in Mannheim (Germany), medpex wholesale GmbH in Ludwigshafen (Germany), as well as Apotheke esando B.V. in Venlo (Netherlands). With this step, the Zur Rose Group is significantly expanding its market leadership in Germany.

Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact
Pascale Ineichen, spokesperson
Email: media@zurrose.com, phone: +41 52 724 08 18

Financial Calendar
23 January 2019 Sales 2018
21 March 2019 Annual Results 2018
17 April 2019 Q1/2019 Trading Update
23 May 2019 Annual General Meeting
21 August 2019 2019 Half-Year Results
23 October 2019 Q3/2019 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest online pharmacy and one of the leading medical wholesalers in Switzerland. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management in order to increase therapy safety. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, cost units and industry.

The Zur Rose Group is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. The company employs over 1,000 people at various locations and generated a turnover of CHF 983 million in the 2017 financial year. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). The CHF 115 million corporate bond issued in July 2018 is also listed on the SIX Swiss Exchange (securities number 42146044, ISIN CH0421460442, ticker ZRO18). Further information at zurrosegroup.com



End of Corporate News


Language: English
Company: Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Switzerland
Phone: +41 52 724 08 14
Internet: www.zurrosegroup.com
ISIN: CH0042615283
Listed: SIX Swiss Exchange

 
End of News EQS Group News Service

762077  07.01.2019 

fncls.ssp?fn=show_t_gif&application_id=762077&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZUR ROSE GROUP AG
06/05COOPERATION BETWEEN MIGROS GROUP AND : Zur Rose and Migros step up cooperation
EQ
05/23ZUR ROSE : shareholders adopt all proposals
EQ
04/30ZUR ROSE : publishes invitation to the Annual General Meeting of Shareholders on..
EQ
04/17ZUR ROSE : grows 28 per cent in the first quarter of 2019
EQ
04/15ZUR ROSE : nominates three new board members
EQ
03/21ZUR ROSE : accelerates growth
EQ
03/12ZUR ROSE : accelerates internationalisation
EQ
03/04ZUR ROSE : Change on the Board of Directors of the Zur Rose Group
EQ
01/23ZUR ROSE : realised its expansion goals in 2018 and grew by over 20 percent
EQ
01/07ZUR ROSE GROUP : Acquisition of medpex successfully concluded
EQ
More news
Financials (CHF)
Sales 2019 1 558 M
EBIT 2019 -27,9 M
Net income 2019 -29,5 M
Debt 2019 81,0 M
Yield 2019 -
P/E ratio 2019 -25,0x
P/E ratio 2020 -219x
EV / Sales2019 0,56x
EV / Sales2020 0,51x
Capitalization 795 M
Chart ZUR ROSE GROUP AG
Duration : Period :
Zur Rose Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZUR ROSE GROUP AG
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 135,33  CHF
Last Close Price 91,70  CHF
Spread / Highest target 63,6%
Spread / Average Target 47,6%
Spread / Lowest Target 21,0%
EPS Revisions
Managers
NameTitle
Walter Oberhänsli Chief Executive Officer & Executive Director
Stefan Feuerstein Chairman
Marcel Ziwica Chief Financial Officer
Thomas Schneider Vice Chairman
Volker Amelung Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ZUR ROSE GROUP AG2.23%807
WALGREENS BOOTS ALLIANCE-21.06%49 357
MCKESSON CORPORATION25.02%25 741
AMERISOURCEBERGEN15.34%18 035
CARDINAL HEALTH-0.45%13 234
SINOPHARM HOLDING CO LTD-9.12%11 351